Upgrade to SI Premium - Free Trial

ResMed (RMD) PT Raised to $212 at Oppenheimer

August 6, 2020 8:14 AM
Oppenheimer analyst Suraj Kalia raised the price target on ResMed (NYSE: RMD) to $212.00 (from $200.00) while maintaining an Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles